Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

LEXX

Insider Sentiment (TTM):

Last Purchase:2025-07-30Last Sale:2024-07-31Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:1,472,162Shares Outstanding:24,887,446Institutional Ownership Pct.:5.92%

Earnings Market Reaction:

Filing Date:2026-07-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-05-31	2026-02-28	2025-11-30	2025-08-31	2025-05-31	2025-02-28	2024-11-30	2024-08-31	2024-05-31	2024-02-29	2023-11-30	2023-08-31
Assets
Cash And Cash Equivalents At Carrying Value	3	5	4	2	5	6	8	6	8	5	2	1
Other Short Term Investments	-	-	-	0	-	-	-	0	-	-	-	-
Short Term Investments	0	0	0	-	-	-	-	-	-	-	-	-
Marketable Securities Current	0	0	0	0	0	0	0	0	0	0	0	0
Assets Current
Assets Current	4	6	5	3	6	8	9	8	9	5	3	2
Accounts Receivable Net Current	0	0	0	0	0	0	0	0	0	0	1	0
Prepaid Expense And Other Assets Current	0	0	1	1	1	1	0	1	0	0	0	1
Inventory Net	-	-	-	-	-	-	-	-	-	-	-	0
Long Term Investments And Receivables Net	0	0	0	0	0	0	0	0	-	-	-	0
Finance Lease Right Of Use Asset	-	0	0	0	0	0	0	0	0	0	0	0
Other Indefinite Lived Intangible Assets	-	0	0	0	1	1	1	1	-	-	-	-
Intangible Assets Gross Excluding Goodwill	-	-	-	-	-	-	-	1	0	1	0	0
Assets Noncurrent
Assets Noncurrent	1	1	1	1	1	1	1	1	1	1	1	1
Operating Lease Right Of Use Asset	0	-	-	-	-	-	-	-	-	-	-	-
Finite Lived Intangible Assets Net	0	-	-	-	-	-	-	-	-	-	-	-
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	0	0	0	0
Assets	5	6	6	4	7	9	10	9	10	6	4	3
Liabilities And Stockhold…
Deferred Revenue	-	-	-	-	-	-	-	0	-	-	-	0
Accounts Payable And Accrued Liabilities Current	0	0	1	1	1	2	0	1	0	0	0	0
Finance Lease Liability Current	-	-	-	-	-	-	-	0	0	0	0	0
Liabilities Current
Liabilities Current	0	0	1	1	1	2	0	1	0	0	0	0
Deferred Revenue Current	-	-	-	0	0	0	0	0	-	-	-	-
Operating Lease Liability Current	0	0	0	0	0	0	0	0	-	-	-	-
Finance Lease Liability Noncurrent	-	-	-	-	-	-	-	0	0	0	0	0
Operating Lease Liability Noncurrent	0	0	0	0	0	0	0	0	-	-	-	-
Liabilities	0	0	2	2	2	2	0	1	0	0	0	0
Stockholders Equity
Share Capital
Capital
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	73	73	70	67	66	64	64	60	60	54	51	49
Retained Earnings Accumulated Deficit	-68	-67	-65	-63	-61	-57	-54	-52	-49	-48	-47	-46
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	0	0
Stockholders Equity	4	6	5	3	5	7	9	8	10	6	4	3
Minority Interest	-0	-0	-0	-	-0	-0	-0	-0	-0	-0	-0	-0
Liabilities And Stockholders Equity	5	6	6	4	7	9	10	9	10	6	4	3
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	220	220	220	220	220	220	220	220	220	220	220	220
Common Stock Shares Issued	25	25	22	20	20	18	17	16	16	12	10	8
Shares Outstanding	25	25	22	20	19	17	17	16	16	12	10	8

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-10.38%	2.47%	28.55%	-37.76%	-35.00%	-42.86%	-40.95%	-	-	-	-	-
2025	-18.06%	-31.94%	-20.37%	-23.40%	-30.14%	-36.17%	1.32%	23.50%	5.40%	-46.51%	-30.37%	-42.84%
2024	15.23%	93.38%	140.40%	15.93%	44.07%	2.96%	34.05%	40.14%	8.24%	4.69%	-10.80%	-24.88%
2023	-	-	-	-	-	-	8.70%	20.77%	20.77%	3.25%	22.76%	86.99%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-05-31	2026-02-28	2025-11-30	2025-08-31	2025-05-31	2025-02-28	2024-11-30	2024-08-31	2024-05-31	2024-02-29	2023-11-30	2023-08-31
Liquidity Ratios
Current Ratio	10.60	26.88	3.68	2.32	3.90	4.24	29.64	7.18	58.27	66.29	21.63	8.03
Quick Ratio	9.56	24.74	3.10	1.56	3.35	3.77	28.15	6.10	55.84	63.02	20.57	5.99
Working Capital	3.68M	5.56M	3.91M	1.97M	4.32M	5.90M	8.53M	6.80M	8.94M	5.34M	2.57M	1.88M
Leverage & Debt
Debt to Equity	0.10	0.04	0.34	0.60	0.30	0.28	0.04	0.16	0.03	0.03	0.08	0.15
Interest Coverage TTM	-	-	-	-	-796.20	-655.93	-510.35	-401.95	-365.59	-188.72	-138.41	-151.29
Debt Ratio	0.09	0.04	0.25	0.38	0.23	0.22	0.04	0.14	0.03	0.03	0.07	0.13
Efficiency & Turnover
Asset Turnover TTM	0.03	0.05	0.07	0.11	0.07	0.07	0.07	0.08	0.05	0.07	0.06	0.04
Days Sales Outstanding TTM	382.99	185.08	122.90	135.17	167.88	238.83	293.16	110.52	170.60	224.78	542.89	265.00
Receivables Turnover TTM	0.95	1.97	2.97	2.70	2.17	1.53	1.25	3.30	2.14	1.62	0.67	1.38
Per Share Metrics
Diluted EPS TTM	-0.31	-0.39	-0.50	-0.66	-0.62	-0.54	-0.44	-0.47	-0.35	-0.50	-0.67	-1.01
Free Cash Flow Per Share TTM	-0.30	-0.38	-0.39	-0.54	-0.50	-0.43	-0.38	-0.32	-0.31	-0.44	-0.58	-0.74
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	-	-	99.61%	99.56%	99.48%	99.45%	98.96%	98.82%	95.62%	92.56%	86.07%
Operating Profit Margin TTM	-3,973.16%	-2,571.89%	-2,062.00%	-1,683.01%	-1,850.10%	-1,785.00%	-1,469.99%	-1,239.16%	-1,145.21%	-1,327.26%	-2,165.77%	-2,888.50%
Net Profit Margin TTM	-3,981.35%	-2,587.83%	-2,067.09%	-1,686.00%	-1,852.36%	-1,787.37%	-1,476.28%	-1,251.12%	-1,188.31%	-1,354.05%	-2,200.98%	-2,946.36%
Growth Metrics
Net Revenue Growth (1Y)	-68.50%	-30.03%	5.05%	52.05%	51.23%	31.16%	80.04%	105.24%	31.23%	20.64%	-19.53%	-11.43%
Net Income Growth (1Y)	-32.30%	1.31%	47.09%	104.90%	135.74%	73.13%	20.76%	-12.85%	-29.82%	-21.40%	-13.65%	-8.31%
EPS Growth (1Y)	-46.58%	-28.52%	15.50%	65.62%	90.55%	22.14%	-28.65%	-55.40%	-64.08%	-62.24%	-50.17%	-32.57%
Valuation Metrics
P/E TTM	-1.93	-1.83	-2.25	-1.45	-1.75	-2.75	-4.95	-10.64	-12.71	-7.87	-2.55	-1.27
P/B TTM	3.43	2.80	5.36	6.61	3.86	3.82	3.86	8.07	6.31	6.95	4.59	3.17
P/S TTM	76.92	47.27	46.41	24.38	32.39	49.08	73.05	133.15	151.01	106.58	56.04	37.56
Market Cap	14.92M	17.40M	24.23M	17.21M	19.95M	25.81M	36.30M	61.82M	61.50M	42.74M	15.47M	8.50M
Enterprise Value	11.45M	12.27M	19.94M	15.41M	15.36M	19.34M	28.22M	55.46M	53.19M	38.18M	13.67M	7.31M
Calculated Values
Free Cash Flow TTM	-7.50M	-9.42M	-8.71M	-10.48M	-9.77M	-7.47M	-6.65M	-5.12M	-4.88M	-5.41M	-5.97M	-6.02M
Net Debt	-3.48M	-5.13M	-4.28M	-1.80M	-4.59M	-6.47M	-8.08M	-6.36M	-8.32M	-4.56M	-1.80M	-1.19M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-07-30Purchase

Owner: Bunka, Christopher

Title: -

Shares: 11,900

Price/Share: $0.91

Value: $10,829.00

Shares Owned: 281,912

Relationship: Director

Ownership: Indirect

2025-07-29Purchase

Owner: Docherty, John Martin

Title: President & CSO

Shares: 5,376

Price/Share: $0.93

Value: $4,999.68

Shares Owned: 5,376

Relationship: Director,Officer

Ownership: Direct

2025-07-29Purchase

Owner: Christopher, Richard

Title: Chief Executive Officer

Shares: 15,000

Price/Share: $0.91

Value: $13,650.00

Shares Owned: 65,000

Relationship: Director,Officer

Ownership: Direct

2025-07-29Purchase

Owner: Mckechnie, William Edward

Title: -

Shares: 5,000

Price/Share: $0.91

Value: $4,550.00

Shares Owned: 18,191

Relationship: Director

Ownership: Direct

2025-07-29Purchase

Owner: Carle, Vanessa

Title: Secretary

Shares: 750

Price/Share: $0.91

Value: $682.50

Shares Owned: 750

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-07-30	Bunka, Christopher	Director	-	Indirect	Purchase	11,900	0.91	$10,829.00	281,912	4
2025-07-29	Docherty, John Martin	Director,Officer	President & CSO	Direct	Purchase	5,376	0.93	$4,999.68	5,376	4
2025-07-29	Christopher, Richard	Director,Officer	Chief Executive Officer	Direct	Purchase	15,000	0.91	$13,650.00	65,000	4
2025-07-29	Mckechnie, William Edward	Director	-	Direct	Purchase	5,000	0.91	$4,550.00	18,191	4
2025-07-29	Carle, Vanessa	Officer	Secretary	Direct	Purchase	750	0.91	$682.50	750	4
2024-12-03	Christopher, Richard	Officer	Chief Executive Officer	Direct	Purchase	27,172	2.47	$67,114.84	50,000	4
2024-08-12	Turkel, Catherine C.	Director	-	Direct	Purchase	1,600	3.13	$5,008.00	3,100	4
2024-07-31	Carle, Vanessa	Officer	Secretary	Direct	Sale	2,567	4.00	$10,268.00	0	4
2023-02-09	Turkel, Catherine C.	Director	-	Direct	Purchase	1,500	2.84	$4,260.00	1,500	4
2022-10-14	Downey, Gregory	Officer	Chief Financial Officer	Direct	Purchase	121	2.09	$252.89	1,954	4/A
2022-10-13	Bunka, Christopher	Director,Officer	Chief Executive Officer	Indirect	Purchase	16,600	2.10	$34,860.00	254,412	4/A
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

5.92%

Inst. Shares: 1,472,162

Shares Outstanding: 24,887,446

2025-12-31

7.65%

Inst. Shares: 1,701,210

Shares Outstanding: 22,225,846

2025-09-30

8.63%

Inst. Shares: 1,687,999

Shares Outstanding: 19,559,179

2025-06-30

11.80%

Inst. Shares: 2,297,063

Shares Outstanding: 19,459,179

2025-03-31

7.11%

Inst. Shares: 1,239,769

Shares Outstanding: 17,449,179

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	1,472,162	24,887,446	5.92%
2025-12-31	1,701,210	22,225,846	7.65%
2025-09-30	1,687,999	19,559,179	8.63%
2025-06-30	2,297,063	19,459,179	11.80%
2025-03-31	1,239,769	17,449,179	7.11%
2024-12-31	1,426,411	17,452,594	8.17%
2024-09-30	1,050,827	15,810,205	6.65%
2024-06-30	2,057,835	15,810,205	13.02%
2024-03-31	888,794	12,387,673	7.17%
2023-12-31	1,135,589	10,311,641	11.01%
2023-09-30	1,758,251	8,091,650	21.73%
2023-06-30	881,592	8,091,650	10.90%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Lexaria Bioscience Corp. (LEXX) — SEC Financial Statements & Analysis

Lexaria Bioscience Corp. (LEXX) is a pharmaceutical preparations company, incorporated in NV. Lexaria Bioscience Corp. trades on Nasdaq as: LEXX. Based on its latest SEC filing (Form 10-Q, period ending 2026-05-31), Lexaria Bioscience Corp. reported a -68.50% year-over-year revenue growth, a Gross Profit Margin of 99.61% (TTM), a Debt-to-Equity ratio of 0.10x, a Price-to-Sales (P/S) ratio of 76.92x (TTM), a Price-to-Book (P/B) ratio of 3.43x (TTM), at a market cap of $14.92M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -68.50%
Gross Profit Margin TTM: 99.61%
Debt To Equity: 0.10x
P/S TTM: 76.92x
P/B TTM: 3.43x
Market Cap: $14.92M

Data as of 2026-05-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Lexaria Bioscience Corp. in?

Lexaria Bioscience Corp. (LEXX) operates in the Pharmaceutical Preparations industry.

What is LEXX's market cap?

Lexaria Bioscience Corp. (LEXX) has a market capitalization of $14.92M as of 2026-05-31.

What exchange does LEXX trade on?

Lexaria Bioscience Corp. (LEXX) trades on the Nasdaq.

Where is Lexaria Bioscience Corp. incorporated?

Lexaria Bioscience Corp. is incorporated in NV.